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Abstract: Renal sympathetic denervation (RSD) as a therapy for patients with resistant 
 hypertension has attracted great interest. The majority of studies in this field have demonstrated 
impressive reductions in blood pressure (BP). However, these trials were not randomized or sham-
controlled and hence, the findings may have been overinflated due to trial biases.  SYMPLICITY 
HTN-3 was the first randomized controlled trial to use a blinded sham-control and ambulatory 
BP  monitoring. A surprise to many was that this study was neutral. Possible reasons for this 
neutrality include the fact that RSD may not be effective at lowering BP in man, RSD was not 
performed adequately due to limited operator experience, patients’ adherence with their anti-
hypertensive drugs may have changed during the trial period, and perhaps the intervention only 
works in certain subgroups that are yet to be identified. Future studies seeking to demonstrate 
efficacy of RSD should be designed as randomized blinded sham-controlled trials. The efficacy 
of RSD is in doubt, but many feel that its safety has been established through the thousands of 
patients in whom the procedure has been performed. Over 90% of these data, however, are for 
the Symplicity™ system and rarely extend beyond 12 months of follow-up. Long-term safety 
cannot be assumed with RSD and nor should it be assumed that if one catheter system is safe 
then all are. We hope that in the near future, with the benefit of well-designed clinical trials, the 
role of renal denervation in the management of hypertension will be established.
Keywords: resistant hypertension, renal denervation, sympathetic nervous system, symplicity
Introduction
Hypertension is a major cause of cardiovascular morbidity and mortality.1 
Pharmacological therapies have significantly improved the outcomes of those with 
the condition. However, an estimated 50% of the hypertensive population remain 
uncontrolled with a blood pressure (BP) .140/90 mmHg, of whom a subgroup fulfill 
the diagnostic criteria for resistant hypertension.2
For those with resistant hypertension, pharmacological therapy is inadequate and 
alternative options are required. An overactive sympathetic nervous system (SNS) 
has long been shown to be an important driver of hypertension.3,4 Indeed, before the 
advent of orally effective and safe BP lowering drugs in the 1950s, surgical sympa-
thetic denervation was offered to those patients with malignant hypertension.5 Recent 
technological advances have enabled physicians to reinvent this historic treatment 
by performing denervation of the renal sympathetic nerves through a percutaneous 
route. Initial clinical trials suggested that renal sympathetic denervation (RSD) could 
revolutionize the landscape of therapy for resistant hypertension, but more recent 
developments have cast a shadow of doubt over this concept.6–9
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In this review, we will discuss the physiological basis for 
sympathetic denervation as a treatment for hypertension. We 
will review the technology that underpins RSD devices and 
discuss the preclinical and clinical evidence.
The sympathetic nervous system in 
hypertension
There is a large body of evidence to support the hypothesis that 
elevated SNS activity is intimately involved in the initiation 
and maintenance of hypertension, and a positive correlation 
between SNS activity and BP has been documented.3,4,10 
Hypertensive patients in whom adverse prognostic markers 
are present, such as those with renal failure, heart failure, or 
left ventricular hypertrophy, are recognized to have greater 
SNS activation than those without these adverse markers.3 
Furthermore, medications that attenuate the SNS, including 
inhibitors of the renin–angiotensin–aldosterone system and 
moxonidine are known to lower BP.3,11
The SNS is pervasive and provides innervation to every 
organ in the human body.12 In patients with hypertension, the 
increased activity of the SNS is not universal as some organs 
are spared. Increased noradrenaline (the key neurotransmitter 
of the SNS) spillover has been observed in cerebral, cardiac, 
and renal circulations but not in pulmonary or splanchnic 
when unmedicated hypertensive individuals were compared 
to normotensive controls.13 Furthermore, increased SNS 
discharges to muscle but not skin have been demonstrated 
with microneurography in patients with hypertension.14 This 
suggests that therapies to attenuate SNS overactivity should 
target key organs, which include the kidneys.15
Renal sympathetic innervation
The kidneys are innervated by both efferent (from the central 
nervous system) and afferent (to the central nervous system) 
sympathetic nerves.16 The majority of nerves are unmyeli-
nated type C fibers.17 The efferent nerves are approximately 
25 times more abundant than afferent nerves.18 Stimulation 
of the efferent nerves in several animal models has been 
shown to increase renin secretion through the direct action of 
noradrenaline on β-adrenoreceptors on juxtaglomerular cells, 
promote sodium and water reabsorption at the tubular level 
via activation of α-adrenoreceptors, and reduce renal blood 
flow and glomerular filtration through vasoconstriction, all 
of which are important mechanisms in the pathophysiology 
of hypertension.16,17,19 In a subgroup of ten patients from 
the SYMPLICITY HTN-1 trial, RSD was able to attenuate 
renal efferent nerve activity with a mean 47% reduction in 
noradrenaline spillover.20
The role of the afferent renal nerves in the genesis of 
hypertension is less well established. There are two main 
types of afferent nerves, both predominately found in the 
renal pelvis; one is chemosensitive and responds to nocicep-
tion (adenosine, ischemia, acidosis, inflammation, oxidative 
stress, and angiotensin II) and the other is mechanosensitive 
(also found in the renal cortex) and responds to stretch.16,21 
In animal models, stimulation of the afferent system acti-
vates central nervous system centers known to be involved 
in cardiovascular regulation.17 Conversely, interrupting the 
afferent nerves in diseased states reduces central sympathetic 
outflow particularly to the heart, the kidneys, and peripheral 
vasculature.4,17,22 In humans, peroneal nerve microneurogra-
phy has been used to demonstrate reduced central nervous 
system sympathetic discharge after afferent (and efferent) 
renal denervation following nephrectomy in patients with 
end-stage renal failure23 and after RSD in a patient with 
hypertension.22,24
Surgical sympathetic denervation
Surgical denervation of the renal nerves in both small 
and large animal models of hypertension, have either 
prevented the onset of hypertension or attenuated its 
magnitude.15
In man, limited historic data suggest that nonselective 
sectioning of the sympathetic nerves to the thorax and abdo-
men improved BP control and even survival in patients with 
malignant hypertension.5,25,26 However, success rates were 
variable and side effects such as hypotension, incontinence, 
and sexual dysfunction were common, leading to the demise 
of nonselective surgical sympathectomy once pharmacologi-
cal therapies were introduced.25,26
The renal transplant medicine literature provides more 
contemporary data on the effects of selective surgical renal 
sympathectomy. First, newly transplanted kidneys can func-
tion despite the absence of functioning efferent or afferent 
renal nerves. Second, over time damaged efferent nerves 
begin to reinnervate the kidney and this process is usually 
complete by 12 months.27,28 More data are available from 
animal models, which suggest that the reinnervation is not 
just anatomical but also functional and involves both efferent 
and afferent nerves.29–31 Third, nonfunctioning kidneys can 
promote hypertension through neurohumoral activity. In a 
selected population of patients with hypertension persisting 
after renal transplant, native kidney nephrectomy (which 
involves sectioning of the renal nerves) was associated with 
improved BP control as well as allograft perfusion.32 Selective 
renal sympathectomy (with nephrectomy) was not associ-
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ated with the significant side effects seen in the nonselective 
sympathectomy cohort.
Resistant hypertension
The reported prevalence of uncontrolled hypertension varies 
according to the definition used but is estimated at 30%–50% 
of the population diagnosed with hypertension.2,33 Within 
this group there is a smaller group, who have true resistant 
hypertension, which can be diagnosed when patients have 
an office BP .140/90 mmHg and a mean 24-hour ambula-
tory BP .130/80 mmHg despite being compliant with three 
or more different classes of antihypertensive medications 
including a diuretic.34 There is evidence that this group forms 
5%–10% of the hypertension population, and patients of this 
group suffer a greater incidence of cardiovascular complica-
tions than the group of patients with controlled BP.35 The 
management of this cohort of patients is challenging, and 
one approach is summarized in Figure 1.
Frustratingly, there have been no new classes of antihy-
pertensives added to the specialist’s armory in recent times 
(since 2000, the only newly approved class has been direct 
renin inhibitors).36 Building on previous decades of knowl-
edge of the increased activity of the sympathetic nerves in 
hypertension, coupled with the increased experience in mini-
mally invasive procedures in cardiology, it was a logical step 
to develop and reexamine nonpharmacological techniques to 
attenuate the SNS. Currently, there are four main autonomic 
nervous system modulating devices under investigation for 
the management of resistant hypertension: RSD catheters, 
baroreceptor stimulators, vagal nerve stimulators, and spinal 
cord stimulators (Figure 2).12 In this review we will focus 
on RSD.
Principles of percutaneous RSD
Renal anatomy
The goal of RSD is to permanently destroy a large proportion 
of the renal sympathetic nerves. There have been only two 
contemporary publications, both based on cadaveric human 
data that usefully describe renal nerve anatomy in man. The 
first studied nine renal arteries suggested that over 90% of 
the renal nerves are within 2 mm of the renal artery lumen 
(lumen–intima interface). However, these data were biased 
as the investigators only examined nerves up to 2.5 mm from 
the lumen and used inadequate histological sectioning.37
The second paper studied more renal arteries (20 in 
total), included vessels that had been exposed to hyperten-
sion in vivo and employed more comprehensive histologi-
cal techniques (perfusion-fixing at physiological pressures, 
assessment of complete periarterial nerve distribution, not 
just those encountered in the first 2.5 mm and application of 
immunohistochemistry to distinguish afferent from efferent 
nerves).38 Their key findings were as follows:
Optimize diuretics
Daytime average BP <135/85 mmHg
(ABPM) without treatment
Daytime average BP <135/85 mmHg
(ABPM) with treatment
Daytime average BP ≥135/85 mmHg
(ABPM)
Patient is prescribed three or more anti
hypertensive medications at optimal doses,
including a diuretic if possible
Assess patient for nonadherence and
ensure guideline driven therapy prescribed
(ususlly includes an ACEi or ARB, a Ca2+
channel blocker and a thiazide diuretic
Weight loss in those overweight
increase exercise
limit alcohol intake
avoidance of high salt, low fiber diet
ABPM ABPM
A
B
P
M
Office BP elevated
SBP ≥140 mmHg
or DBP ≥90 mmHg 
Escalation of pharmacological management in resistant hypertension
White-coat hypertension
Controlled hypertension
Uncontrolled hypertension
Treatment-resistant hypertension
Ensure compliance
Lifestyle measures
Investigate for secondary causes of 
hypertension
Discontinue substances that may
elevate blood pressure
If K+≤4.5 mmol/L
If K+>4.5 mmol/L
Other agents with limited evidence-base
Adrenoreceptor blockers
Double dose of current thiazide diuretic
or add loop diuretic
Add spironolactone, eplerenone, or amiloride
Consider enrollment in clinical trial
Pharmacological agent
Device therapy
Vasodilators (hydralazine)
Centrally acting α-agonists (methyldopa,
clonidine or moxonidine)
and/or
α-blocker
and/or
β-blocker (heart rate dependent)
Figure 1 Flowchart summarizing the diagnosis and management algorithm in patients with resistant hypertension.
Note: Reproduced from Patel H, Hayward C, de Silva R. An approach to diagnosis and management of resistant hypertension. J Pract Cardiovasc Sci. 2015;1(1):60–64 (http://
creativecommons.org/licenses/by-nc-sa/3.0/).34
Abbreviations: ABPM, ambulatory blood pressure monitor; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; ACei, angiotensin converting 
enzyme inhibitor; ARB, angiotensin II receptor blocker; Ca2+, calcium; K+, potassium.
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1. Renal nerve anatomy in hypertensive patients is similar 
to the anatomy in those with normal BP.
2. The number of nerves are greater around the proximal 
and middle segments of the renal artery than the distal.
3. The nerves approximate closer to the renal artery lumen 
as they progress from the aorta to the renal hilum. Prior 
to any renal artery bifurcation, 90% of the renal nerves 
are within 6.4 mm of the renal artery lumen. However, 
after any bifurcation, 90% of the nerves are within 3 mm 
of the lumen.
4. A larger proportion of nerves pass anterior, superior, and 
inferior to the renal artery as opposed to posterior to it.
5. Sympathetic nerves are also associated with smaller 
accessory renal arteries.
Based on these data, the renal sympathetic nerves lie 
in close proximity to the renal artery (usually within the 
adventitia), and it is conceivable that they could be targeted 
by thermal energy using either radio frequency (RF) or 
ultrasound (US) delivered from a catheter within the renal 
artery lumen.39
Brain
Baroreceptors
SCS
Renal denervation
VNS
BRS
VNS
Heart
Spinal cord
Renal artery
SCS
Baroreceptor
Carotid
artery
Vagus
nerve
Figure 2 The four sites of action of autonomic nervous system modulating devices.
Note: Reprinted from International Journal of Cardiology, 170(2), Patel HC, Rosen SD, Lindsay A, Hayward C, Lyon AR, di Mario C, Targeting the autonomic nervous system: 
measuring autonomic function and novel devices for heart failure management, 107–117, Copyright © (2013), with permission from elsevier.12
Abbreviations: BRS, baroreceptor stimulator; vNS, vagal nerve stimulator; SCS, spinal cord stimulator.
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The original RSD trials in humans recommended that 
all ablations should be limited to the main vessel before any 
bifurcations.6,7 However, the latest histology data suggest that 
it might be preferential to target the distal vessel, where the 
renal nerves lie closer to the arterial lumen. Henegar et al40 
compared the effects of RSD at the renal artery ostium, main 
renal artery before any bifurcation and postbifurcation upon 
renal noradrenaline levels in pigs. They concluded that a strat-
egy of performing postbifurcation ablation was more effective 
at attenuating the activity of the renal SNS. This approach is 
yet to be translated to humans and, at present, should only be 
undertaken within the auspices of a clinical trial to ensure 
there are no safety concerns from possible thermal injury to 
the psoas muscles, small bowel, and liver.41
Biophysics and denervation catheters
During RSD, electrical energy at the denervation catheter 
tip is converted to either RF or US energy, which penetrates 
through the renal artery wall and “excites” the periartery 
cells.39 This “excitation” creates friction between the cells 
generating thermal energy. Once the tissue temperature 
reaches 50°C, irreversible cell death ensues and a lesion is 
created. Though the penetration of RF and US energy is likely 
to be just a few millimeters, the lesion depth extends further 
than this due to conduction of thermal energy from the initial 
and more superficial structures that are heated first.39
Factors that influence the size of lesion created include 
power delivery, electrode–tissue contact, tissue impedance, 
and tissue temperature.39 During a procedure, the operator 
only has the ability to alter electrode–tissue contact. Power 
delivery is governed by proprietary and automated algorithms 
driven by measurement of tissue impedance and temperature 
taken at the electrode tip. There are six RSD systems with the 
Conformité Européenne mark, each with important design 
variations, such that their efficacy and safety should be con-
sidered individually rather than as a class-effect (Table 1).
The Spyral™ (Medtronic, Dublin, Ireland) and Vessix™ 
(Boston Scientific, Marlborough, MA, USA) system may 
be used in renal arteries with diameters as small as 3 mm, 
whereas with all the others a minimum artery diameter of 
4 mm is recommended. The Iberis™ (Terumo Medical Cor-
poration, Tokyo, Japan) and the Radiance™ (5Fr version of 
Table 1 Currently available Ce-marked renal denervation catheters
Catheter Energy Configuration Electrode Balloon Cooling Delivery Ablation  
timea  
(s/artery)
Maximum  
power (W)
Vascular 
access  
size (Fr)
Symplicity™  
(Medtronic)
RF Unipolar Single No Blood Deflectable tip 540 8 6
Spyral™  
(Medtronic)
RF Unipolar Multiple No Blood Monorail 60 8 6
vessix™  
(Boston Scientific)
RF Bipolar Multiple Yes None Over-the-wire 30 1 8
enligHTN™  
(St Jude)
RF Unipolar Multiple No Blood Deflectable tip 90 6 8
Iberis™  
(Terumo)
RF Unipolar Single No Blood Deflectable tip 540 8 4
Paradise™  
(Recor)b
US Unipolar Single Yes Close 
irrigated
Over-the-wire 50–150 30 6
Notes: aMinimum estimated time of RF delivery; bthere is also a 5Fr version of Paradise™ called Radiance™ that may be used via the radial artery.
Abbreviations: RF, radiofrequency; US, ultrasound; Ce, Conformité européenne.
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Treat distal to proximal
≥5 mm
spacing
A
B
Figure 3 Renal denervation procedure using the Symplicity™ catheter (A).
Notes: Ablations are applied as shown in a helical pattern, including at least one 
of each anterior, posterior, superior, and inferior positions (B). Reproduced from 
Patel HC, Hayward C, Di Mario C. SYMPLICITY HTN 3: the death knell for renal 
denervation in hypertension? Glob Cardiol Sci Pract. 2014;2014(1):94–98.8
Paradise™ [Recor, Amsterdam, the Netherlands]) catheters 
can be used via the radial artery approach (all other catheters 
mandate operation through the femoral artery).
The maximum lesion size created by these catheters 
remains poorly reported.41 A recent review identified only four 
publications that adequately detailed lesion characteristics 
involving only the Symplicity™ (Medtronic), EnligHTN™ 
(St Jude, St Paul, MN, USA), and Paradise™ systems.41 
The maximum depth of thermal injury varied from 2 to 12 
mm.18,42,43 There needs to be more clarity about the capabili-
ties of each system as catheters that are able to create deeper 
lesion might disrupt a greater proportion of periarterial nerves 
and hence, be more efficacious, though this would have to be 
balanced against the increased risk of inadvertent damage to 
other abdominal structures.41 Recently, standards on report-
ing of preclinical evaluation of RSD have been published and 
should hopefully help improve our understanding of efficacy 
and risks of the various denervation systems.44
It should also be noted that currently, it is not recom-
mended to perform RSD in regions of the renal artery with 
significant renal atheroma. Two underlying reasons for this 
are as follows: 1) the safety of this approach is unknown, in 
particular whether it may cause plaque rupture or acceler-
ate atheroma progression; and 2) it is doubtful whether the 
radiofrequency energy will be able to penetrate through the 
atheroma to the adventitia, where the sympathetic nerves 
are and therefore, might expose the patient to risk without 
any likely benefit.
The renal denervation procedure
The procedure is performed in an angiography suite. Local 
anesthesia is used for arterial access. Intravenous opioids 
and sedation are required during the application of RF or 
US energy as this always stimulates the C-type pain fibers 
associated with the renal sympathetic nerves. Intravenous 
heparin is administered during the procedure. Some centers 
also advocate 2–4 weeks of antiplatelet agents to minimize 
the risk of intra-arterial thrombus formation. Fluoroscopy 
with radio-opaque contrast is employed to position the chosen 
RSD catheter in the renal artery.
The original ablation strategy was that four to six lesions 
would be created in a helical pattern (such that all four seg-
ments of the artery were treated) in both renal arteries in the 
proximal or middle segments prior to any major bifurcation 
(Figure 3). To those who have performed RSD, it is appar-
ent that when using the single electrode design catheters 
(Symplicity™ or Iberis™), the operator cannot be certain 
whether the anterior or posterior segment of the renal artery 
is being treated, due to the limitation of two-dimensional 
fluoroscopic imaging. The multielectrode catheters (Table 
1) are designed to create circumferential or helical ablation 
lesions in a more rapid and consistent fashion.
The biggest intraprocedural challenge that remains unre-
solved is the lack of a marker to inform the operator whether 
the ablation has been sufficient to adequately attenuate renal 
sympathetic nerve activity.
Trials of RSD
Initial evidence for the efficacy of a percutaneous approach 
in achieving sympathetic denervation came from animal 
studies.15 In normotensive dogs, electrical stimulation of 
renal nerves from within the renal artery increased systolic 
BP by at least 20 mmHg.45 However, when the stimulation 
protocol was repeated after percutaneous RSD, the systolic 
BP response was attenuated with a mean increase of only 
2 mmHg. Henegar et al42 achieved a 9 mmHg drop in mean 
arterial pressure in nine hypertensive and obese dogs fol-
lowing RSD.
The first procedure in man was performed in 2007 as 
part of the proof-of-concept SYMPLICITY HTN-1 study 
using the Symplicity™ catheter.6 It was performed across 
five centers in Australia and Europe. Fifty patients with 
office systolic BPs .160 mmHg despite being on three or 
more antihypertensives (including a diuretic) were recruited. 
Forty-five of these patients underwent the procedure as five 
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did not have suitable renal anatomy. As an added safety fea-
ture, the first ten patients underwent staged RSD, where the 
second renal artery was treated 1 month after the first. This 
pilot study provided evidence for the safety and tolerability 
of RSD. After publishing the initial results, the investigators 
extended the pilot to 153 patients of whom 88 were followed 
up for 3 years.46 Four major immediate complications were 
reported: one renal artery dissection and three femoral artery 
complications (pseudoaneurysm or significant hematoma). 
There were four cases of renal artery stenosis in this extended 
follow-up cohort, and it is unclear whether these represented 
intrinsic disease progression or a complication of the proce-
dure. The finding that caught the attention of the cardiology 
community, however, was the impressive reduction in office 
BP observed at 6 months of 22/10 mmHg, which persisted 
with a slight further decrease after 3 years of follow-up.
The same key investigators then devised a randomized 
open-label trial, SYMPLICITY HTN-2.7 At 6 months post-
randomization, office BP data were available for 49 patients 
who underwent RSD and 52 who were allocated as controls. 
The between-group difference in reduction in BP was 
33/11 mmHg (P,0.0001) in favor of the active treatment. 
Twenty patients in the active arm also underwent ambulatory 
monitoring and they achieved an 11/7 mmHg mean reduction 
in BP. The only significant complication reported was the 
occurrence of one femoral artery pseudoaneurysm.
These strong signals for efficacy and safety captured the 
imagination of interventionists and hypertension specialists 
alike. Multiple studies to investigate the efficacy of RSD 
were subsequently launched; the majority of which showed 
a 10–30 mmHg reduction in office systolic BP following 
RSD.47 If even a 10 mmHg effect was genuine, then this 
would be expected to deliver an impressive 41% reduction 
in stroke as well as a 22% reduction in coronary heart dis-
ease events.48
Table 2 summarizes the findings of a recent PubMed 
search, using the terms “renal denervation” and “hyperten-
sion” to identify unique human clinical trials. The definitions 
used by these trials to diagnose resistant hypertension dif-
fered, which often resulted in recruitment of patients with 
various stages of hypertension. The majority of the early 
trials did not use 24-hour ambulatory monitoring to exclude 
white-coat hypertension. The impact of this omission is large; 
in a registry of 8,295 patients with apparent resistant hyper-
tension (office BP $140 and/or 90 mmHg, while on three 
antihypertensive drugs including a diuretic), 37.5% of the 
cohort were reclassified as having white-coat hypertension 
after ambulatory monitoring.49 Patients with pseudoresistant 
hypertension are unlikely to benefit from RSD.50
Three-quarter of the studies to-date have been uncon-
trolled, which raise the concern that much of the efficacy data 
of RSD may be overinflated due to bias. In particular, three 
key biases were inherent in the majority of RSD studies:51
1. Regression to the mean: this occurs when a variable 
such as office BP has inherent biological variability and 
patients are selected on the basis of recording a high 
value. In doing so, the study criteria selects patients who 
might be having a “big-day” and experiencing higher than 
their usual BP; consequently, the higher the threshold for 
selection, the larger the statistical expectation of a fall 
Table 2 Summary of the published renal denervation trials, including number of trials published, number of patients denervated using 
different catheters, and reported complications
Study types Uncontrolled68–109 Case-control110–114 Randomized control7,9,53–58 Total
Number published 42 (76%) 6 (11%) 7 (13%) 55
Number denervations 2,713 (73%) 276 (7%) 743 (20%) 3,732
 Symplicity™ 2,533 237 730 3,500 (94%)
 enligHTN™ 58 0 0 58 (2%)
 Paradise™ 11 0 0 11 (,1%)
 vessix™ 8 0 0 8 (,1%)
 Iberis™ 6 0 0 6 (,1%)
 OneShot™a 9 0 0 9 (,1%)
 eP 88 39 13 140 (4%)
Complications 38 (1.4%) 5 (1.8%) 13 (1.7%) 56
 Renal artery 13 0 4 17 (0.5%)
 Renal function 8 0 4 12 (0.3%)
 Femoral artery 17 5 5 27 (0.7%)
Notes: aThe OneShot denervation system is no longer produced. Renal artery complications include dissection and stenosis. Renal function complications include .50% 
deterioration in renal function or new end-stage renal failure. Femoral artery complications include pseudoaneurysm or significant hematoma. 
Abbreviation: eP, cardiac electrophysiological study catheter.
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in the variable, without any intervention. The best way 
to mitigate the effects of this bias is to have a prolonged 
run-in phase with multiple BP measurements taken across 
several weeks prior to assess trial eligibility.36 Decreasing 
the BP threshold for trial entry, would also reduce the 
magnitude of regression to the mean: the majority of 
RSD trials required an office systolic BP $160 mmHg, 
which could be reduced to $140 mmHg (a commoner 
threshold used in hypertension trials). Finally, the adop-
tion of a randomized design would enable comparison 
of any responses seen in the active arm against those in 
the control.
2. Unintentional bias by clinical observers: typically the 
majority of trials have used office-measured BP as an 
end point. Regardless of whether the physician is blinded 
to the treatment allocation, they are likely to reject 
measurements which appear inconsistent and against 
expectation. It has been shown that using ambulatory 
BP monitoring to assess response reduces this bias. A 
further benefit of ambulatory monitoring is in selecting 
out patients who have white-coat effects and hence, do 
not fulfill the diagnostic criteria for resistant hypertension 
(Figure 1).
3. Change in adherence to therapy: it is plausible that as 
a result of increased attention and by exposure to an 
invasive procedure that trial participants became bet-
ter educated on the importance of BP control and this 
may have improved medication adherence. Unlike in 
the majority of pharmaceutical trials, where preexisting 
antihypertensive agents are withdrawn in the run-in phase, 
in the denervation trials these medications are continued. 
When BP responses in the placebo arm of pharmaceutical 
double-blind randomized controlled trials (RCTs) (n=52) 
in nonresistant hypertension were analyzed, the greater 
the number of nonstudy BP medications taken at ran-
domization, the greater the reduction in BP was noted.36 
The only way to account for this bias, is to either design 
a trial in resistant hypertension where participants are 
included after being withdrawn from their usual medica-
tions or perhaps more acceptable is to adopt a randomized, 
blinded-sham control design so that any response seen in 
the active arm can be balanced against that seen in the 
sham arm.52
The limitations of the uncontrolled, nonrandomized 
and unblinded trials of RSD in resistant hypertension were 
widely overlooked and led to a feverish uptake of this novel 
treatment involving thousands of patients across Europe, 
Asia, and Australasia.
RCTs
Six RCTs followed SYMPLICITY HTN-2 with two using 
a blinded sham control and ambulatory monitoring to select 
patients and assess their response. These trials were designed 
to best mitigate the previously described biases. SYMPLIC-
ITY HTN-3 was the larger of the two and randomized a 
total of 535 patients.9 It was primarily launched to fulfill the 
regulatory requirements in the USA to receive Food and Drug 
Administration approval. In the active arm, there was a large 
decrease in office (14.1 mmHg) and ambulatory (6.8 mmHg) 
systolic BP; however, this was not significantly different to the 
reduction seen in the BP of those in the sham-controlled arm. 
In subgroup analysis, RSD appeared more effective in non-
black compared to black individuals. The clinical significance 
of this remains unclear but suggests that there are subgroups 
of patients who might benefit from RSD, and more work needs 
to be undertaken to identify these groups better.
The neutral result of SYMPLICITY HTN-3 was unex-
pected and effectively curbed much of the inflated enthusiasm 
for performing RSD outside of clinical trials. Potential rea-
sons for the neutrality of this trial have been widely discussed, 
but a frequently quoted one was that the procedure was not 
performed adequately.8 The trial was exclusively undertaken 
in the USA, where the operators had no prior experience of 
RSD. Only 26 of the 111 operators involved in SYMPLIC-
ITY HTN-3 had performed five or more denervations. In post 
hoc analysis, there was a suggestion that those patients who 
had more extensive and comprehensive ablations achieved 
a greater reduction in BP.53 This suggests that the newer 
catheters with multiple electrodes, which were designed to 
deliver an anatomically comprehensive ablation, might be 
more effective.
The 11.7 mmHg decrease in systolic BP seen in the 
sham arm of SYMPLICITY HTN-3 also received scrutiny 
as it was significantly different to the 1 mmHg increase 
documented in the control arm of SYMPLICITY HTN-2.36 
A subsequent meta-analysis estimated the expected mean 
systolic BP response in the blinded control arms of resistant 
hypertension trials to be -8.8 mmHg.36 The paradoxical 
response seen in SYMPLICITY HTN-2 might represent a 
reverse Hawthorne effect, whereby patients allocated to the 
control arm purposefully changed their behavior (including 
reduced adherence to medication) to increase the likelihood 
of being eligible for an opportunity to crossover and receive 
RSD after 6 months. Blinding patients to randomization 
allocation would reduce this bias.
The only other trial which employed a sham control was 
smaller (35 patients allocated to RSD and 34 to control) but 
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was conducted with more experienced operators in Europe.54 
Though the trial failed to meet its primary end point (change 
in ambulatory systolic BP at 6 months as intention-to-treat), 
there was a suggestion of benefit on a per-protocol analysis 
where a significant difference between the active and sham 
arm of the trial was seen (8.3 vs 3.5 mmHg, P=0.042). This 
study was, however, underpowered for its primary end 
point.
Two RCTs that published their findings after SYMPLIC-
ITY HTN-3 both used intensified pharmacology (IP) as an 
open-label active control. These studies used the Simplicity™ 
catheter system and employed ambulatory BP monitoring. In 
the Prague-15 study (n=106), the control group were adminis-
tered spironolactone as an add-on therapy. However, this was 
associated with a higher rate of adverse events in the control 
arm ultimately cumulating in the discontinuation of the drug 
in 39% of patients.55 This study suggested that RSD is just as 
efficacious at lowering BP as spironolactone, but with fewer 
short-term side effects and greater tolerability.
The DENER-HTN (n=101) trial mandated a more 
regimented drug escalation protocol after randomization if 
home BP readings were $135/85 mmHg.56 In contrast, the 
Prague-15 trial stepped-up antihypertensive treatment was 
allowed in both the open-control and the renal denervation 
arms. At the end of the study, the patients were taking more 
BP-lowering medications than at the start, but there remained 
no differences in this respect between the two arms. The 
study concluded that RSD with IP was more efficacious 
than IP alone.
SYMPLICITY HTN-Japan was an open-control trial 
that was discontinued early after the negative results of 
SYMPLICITY HTN-3.57 They had randomized 41 patients 
and at 6 months follow-up did not demonstrate a significant 
difference between the two allocation groups with respect to 
office systolic BP. However, it is important to note that with 
41 patients only, this study was underpowered.
Finally, Pokushalov et al58 evaluated RSD in 27 patients 
with resistant hypertension, who were due to undergo atrial 
fibrillation ablation.58 Participants were randomized to have 
concomitant RSD using the same electrophysiology abla-
tion catheter or nothing. This study had significant biases: 
1) single-center experience, 2) small study size, 3) ambula-
tory BP monitoring was not used, and 4) neither the patients 
nor the investigators who performed the analysis were blinded 
to allocation. Due to these important biases, the results 
pertaining to BP from this study will not be discussed.59 
Perhaps the most interesting finding from this study was that 
they showed a blunted elevation in systolic BP in response 
to high-frequency stimulation from within the right and left 
renal artery following RSD.58 This technique to assess effi-
cacy of RSD has been reproduced by others.60
A summary forest plot of RCT data that used ambulatory 
BP monitoring to measure efficacy is shown in Figure 4. 
A formal meta-analysis of the six properly designed RCTs has 
further failed to show any BP lowering effect from RSD.61
Safety of renal denervation
Table 2 summarizes the reported complications in 55 stud-
ies of RSD in resistant hypertension. The overall composite 
complication rate is 1.5%, which includes vascular access 
site complications (pseudoaneurysm, hematoma), renal 
artery injury (dissection, stenosis), and renal dysfunction 
(.50% change in renal function). The true burden of chronic 
complications (renal artery stenosis, deterioration in renal 
20 10 0 10
Reduction in ambulatory SBP (mmHg)
Blinded; sham control
Blinded; sham control
Open label; active control
Open label; active control
Open label; passive control
Open label; passive control
Favors controlFavors RSD
S-HTN-27 (n=45)
S-J57 (n=41)
Prague-1555 (n=106)
DENER-HTN56 (n=101)
Desch et al54 (n=71)
S-HTN-39 (n=491)
Figure 4 Forest plot showing the effect of renal denervation across key randomized controlled trial on ambulatory SBP.
Notes: Error bars denote mean effect with 95% confidence intervals.
Abbreviations: RSD, renal sympathetic denervation; SBP, systolic blood pressure; S, SYMPLICITY; J, Japanese.
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function), however, cannot be gauged as renal artery imaging 
has not been systematically performed after the procedure, 
the majority of studies are uncontrolled and therefore the 
natural progression in renal function in untreated patients 
with resistant hypertension cannot be directly obtained for 
comparison with those who underwent RSD, and the majority 
of studies did not extend beyond 6 months of follow-up and 
hence, there is limited data to describe any potential harmful 
effects beyond this time point. Finally, since more than 90% 
of the published RSD data have used the Symplicity™ cath-
eter, the safety and efficacy data we have is attributable only 
to this system and should not be generalized to other products. 
Indeed, a small study using optical coherence tomography 
immediately after RSD found differences in the extent of 
vascular damage between balloon and non-balloon-based 
catheter systems.62 These risks and uncertainties should be 
communicated appropriately to patients before consenting 
them to what currently remains a research procedure.
The future
The future of RSD remains uncertain. Currently, the best 
trial evidence suggests that RSD is not effective at lowering 
the BP of patients with resistant hypertension. However, the 
future of RSD will depend on the emerging answers to the 
following:
1. Was the RSD technique ineffective at achieving adequate 
sympathetic denervation? It is difficult to deliver complete 
anatomical ablation with the single electrode Simplic-
ity™ catheter, which was adopted by the majority of 
trials. Future trials should use the newer multielectrode 
catheters and examine whether they are an improvement. 
Furthermore, consideration should be given to whether 
operators ought to target the distal renal artery, where 
renal nerves are in closer proximity to the arterial lumen 
rather than restrict themselves to prebifurcation segments. 
Indeed, in pigs, ablating more distally achieved a greater 
reduction in renal noradrenaline levels.40 Finally, the 
critical limitation of all RSD procedures is the lack of a 
reliable measure of success of denervation. The latter point 
encompasses both intraprocedural markers and pre- and 
postprocedural assessment of the SNS (there is currently 
no gold-standard technique to quantify the SNS).
2. Is trial design the major culprit in creating false optimism 
and will future trials take heed of the lessons of previ-
ous flawed trial design? Along with others, we hope that 
future trials will have a randomized, sham-controlled, 
and blinded design with particular attention to end point 
selection (ambulatory monitors should be used more 
widely to assess BP response); and adequate length of 
follow-up (to assess longevity of any response, ie, do the 
renal sympathetic nerves reinnervate29 and to establish 
long-term safety especially with respect to renal function 
and renal artery stenosis).
3. Have the wrong patients been studied? Resistant hyper-
tension is a complicated condition to manage. Accurately 
diagnosing the condition for clinical study has not been 
performed well in the RSD trials. Very few studies used 
ambulatory monitors to exclude white-coat hypertension 
and those that did found that RSD was not as effective as 
previous trials. By definition, polypharmacy is a feature 
of resistant hypertension, and nonadherence is expected 
to affect up to 50% of patients.63,64 It might have been 
simpler to interpret a study investigating the role of 
denervation in mild or moderate hypertension patients, 
where patients could be safely weaned of any BP lower-
ing agents prior to randomization thereby removing any 
effects due to change in adherence.
4. Is the hypothesis wrong? The role of the renal sympa-
thetic nerves in hypertension has overwhelming support 
from preclinical and clinical studies and should not be 
disputed. However, the SNS is not the only pathway 
involved in hypertension and may not even be the most 
important.65,66 This is illustrated by the finding that other 
effective classes of antihypertensives, such as diuretics, 
calcium channel blockers, and α-adrenoreceptor block-
ers, commonly elevate overall SNS activity.3,11 Further 
evidence comes from an uncontrolled study of 35 patients 
with resistant hypertension in whom no correlation was 
found between the baseline or change in sympathetic 
nerve activity (microneurography) and change in BP 
following RSD.67
Conclusion
There are nine relatively small RCT and blinded trial in 
resistant hypertension (including drugs and devices), which 
is inadequate for such an important clinical problem.36 The 
autonomic nervous system may be an important target in 
this difficult-to-treat condition. We hope that soon, with 
the benefit of well-designed trials, we will know what role, 
if any, renal denervation has to play in the management of 
resistant hypertension.
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